Product Description
Mechanisms of Action: ADORA1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biogen
Company Location: CAMBRIDGE MA 02142
Company CEO: Michel Vounatsos
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Heart Failure, Acute|Acute Kidney Injury|Kidney Diseases|Heart Failure
Phase 2: Heart Failure|Kidney Diseases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
POSEIDON | P2 |
Terminated |
Heart Failure|Kidney Diseases |
2010-01-01 |
24% |
POSEIDON | P2 |
Terminated |
Heart Failure|Kidney Diseases |
2009-12-14 |
|
160HF301 , Trident I | P3 |
Completed |
Kidney Diseases|Acute Kidney Injury|Heart Failure, Acute |
2009-11-10 |
|
TRIDENT-1 | P3 |
Completed |
Heart Failure|Kidney Diseases |
2009-10-30 |
39% |